Cochrane COVID-19 Study Register
Study record
NCT04918914First Published: 2021 Jun 10Updated Date: 2021 Jun 10

Off Label Use of Dapsone in SARS-CoV-2 Hospitalized Patients

  1. Study Type
  2. Interventional
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Single Arm/Controlled Before After
  1. Intervention Assignment
  2. Not Applicable
Reference record

Critical Care Results of SARS-CoV-2 ARDS by Dapsone and Standard COVID-19 Treatment

NCT04918914
Trial registry record
No Results
Abstract Background: Clinicians in pulmonary critical care medicine and critical care medicine considered dapsone administration to treat SARS-CoV-2 inflammasome. Dapsone is useful in the molecular regulation of Nod-like receptor family pyrin domain-containing 3 (NLRP3). Objective: To study the targeting of NLRP3 itself or up-/downstream factors of the NLRP3 inflammasome by dapsone must be responsible for its observed preventive effects, functioning as a competitor. Methods: Patients who were on standard COVID-19 therapy are also after obtaining off label uses and explanation of side effects are started on dapsone 100-200 mg daily along with Cimetadine 400 mg three times daily